Terbinafine transdermal - Crescita Therapeutics

Drug Profile

Terbinafine transdermal - Crescita Therapeutics

Alternative Names: NRI 1002; Penecure; Transcellular antifungal - Crescita

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nuvo Research
  • Developer Crescita Therapeutics
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Onychomycosis in USA (Transdermal, Liquid)
  • 17 Aug 2015 Terbinafine transdermal is still in preclinical trials for Onychomycosis in USA (http://www.nuvoresearch.com/products/pipeline/)
  • 11 Aug 2015 Terbinafine transdermal - Nuvo Research is available for licensing as of 11 Aug 2015. http://www.nuvoresearch.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top